These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1786 related articles for article (PubMed ID: 24519982)

  • 1. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
    Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
    Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.
    Thal DR; Walter J; Saido TC; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):167-82. PubMed ID: 25534025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.
    Rijal Upadhaya A; Capetillo-Zarate E; Kosterin I; Abramowski D; Kumar S; Yamaguchi H; Walter J; Fändrich M; Staufenbiel M; Thal DR
    Neurobiol Aging; 2012 Nov; 33(11):2641-60. PubMed ID: 22305478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease.
    Bossers K; Wirz KT; Meerhoff GF; Essing AH; van Dongen JW; Houba P; Kruse CG; Verhaagen J; Swaab DF
    Brain; 2010 Dec; 133(Pt 12):3699-723. PubMed ID: 20889584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease.
    Kumar S; Wirths O; Theil S; Gerth J; Bayer TA; Walter J
    Acta Neuropathol; 2013 May; 125(5):699-709. PubMed ID: 23525537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
    Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
    Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathology of clinical and preclinical Alzheimer's disease.
    Thal DR; von Arnim C; Griffin WS; Yamaguchi H; Mrak RE; Attems J; Upadhaya AR
    Eur Arch Psychiatry Clin Neurosci; 2013 Nov; 263 Suppl 2():S137-45. PubMed ID: 24077890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"].
    Tamaoka A
    Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease.
    Rasmussen J; Mahler J; Beschorner N; Kaeser SA; Häsler LM; Baumann F; Nyström S; Portelius E; Blennow K; Lashley T; Fox NC; Sepulveda-Falla D; Glatzel M; Oblak AL; Ghetti B; Nilsson KPR; Hammarström P; Staufenbiel M; Walker LC; Jucker M
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):13018-13023. PubMed ID: 29158413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.
    Härtig W; Goldhammer S; Bauer U; Wegner F; Wirths O; Bayer TA; Grosche J
    J Chem Neuroanat; 2010 Sep; 40(1):82-92. PubMed ID: 20347032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
    Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ
    Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease.
    Dickson TC; Vickers JC
    Neuroscience; 2001; 105(1):99-107. PubMed ID: 11483304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.
    Perez-Nievas BG; Stein TD; Tai HC; Dols-Icardo O; Scotton TC; Barroeta-Espar I; Fernandez-Carballo L; de Munain EL; Perez J; Marquie M; Serrano-Pozo A; Frosch MP; Lowe V; Parisi JE; Petersen RC; Ikonomovic MD; López OL; Klunk W; Hyman BT; Gómez-Isla T
    Brain; 2013 Aug; 136(Pt 8):2510-26. PubMed ID: 23824488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease.
    Dickson TC; Saunders HL; Vickers JC
    Neuropathol Appl Neurobiol; 1997 Dec; 23(6):483-91. PubMed ID: 9460714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparan sulfate subdomains that are degraded by Sulf accumulate in cerebral amyloid ß plaques of Alzheimer's disease: evidence from mouse models and patients.
    Hosono-Fukao T; Ohtake-Niimi S; Hoshino H; Britschgi M; Akatsu H; Hossain MM; Nishitsuji K; van Kuppevelt TH; Kimata K; Michikawa M; Wyss-Coray T; Uchimura K
    Am J Pathol; 2012 May; 180(5):2056-67. PubMed ID: 22429964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice.
    Balakrishnan K; Rijal Upadhaya A; Steinmetz J; Reichwald J; Abramowski D; Fändrich M; Kumar S; Yamaguchi H; Walter J; Staufenbiel M; Thal DR
    Acta Neuropathol Commun; 2015 Jul; 3():41. PubMed ID: 26141728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner.
    Thal DR; Capetillo-Zarate E; Schultz C; Rüb U; Saido TC; Yamaguchi H; Haass C; Griffin WS; Del Tredici K; Braak H; Ghebremedhin E
    Acta Neuropathol; 2005 Nov; 110(5):459-71. PubMed ID: 16195918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of cerebral amyloid angiopathy define histopathological phenotypes in Alzheimer's disease.
    Allen N; Robinson AC; Snowden J; Davidson YS; Mann DM
    Neuropathol Appl Neurobiol; 2014 Feb; 40(2):136-48. PubMed ID: 23808763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.
    Gourmaud S; Shou H; Irwin DJ; Sansalone K; Jacobs LM; Lucas TH; Marsh ED; Davis KA; Jensen FE; Talos DM
    Brain; 2020 Jan; 143(1):191-209. PubMed ID: 31834353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 90.